Surgery for Pancreatic Cancer With Oligo-Metastasis

NCT04196816 | Completed

• 1 other identifier: RECHMPL19_0534
• Study Type: observational
• Target: 200
• Locations: 1 country
• Sites: 1

Brief Summary

Pancreatic cancer is increasing in incidence and will be the second leading cause of cancer-related deaths in 2030 in the West. Only 10 to 15% of patients are eligible for curative resection with long-term survival rarely exceeding 20% at 5 years. The management of metastatic or recurrent diseases can not, unfortunately, be recommended to date because of limited data available (INCA 2019). However, recent, low-strength publications have reported encouraging results on the long-term survival of stage IV or recurrent patients. The aim of the present retrospective cohort study is to analyze results of surgery/destruction of metastatic synchronous or metachronous disease or local recurrence in patients with stage IV pancreatic cancer

Conditions

Pancreatic Cancer; Pancreatic Surgery

Keywords

Surgery; Metastasis surgery; Survival; Multimodal treatment; Stage IV

Outcome Measures

Primary Outcomes (1)

• Overall survival

  Overall survival at 3 years (percentage of patients alive). Overall survival (OS) (time from diagnosis until death, regardless of cause)

  3 years

Secondary Outcomes (1)

• Progression-free survival

  3 years

Eligibility Criteria

• Age: 18 Years - 95 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients who had resection or destruction of one or more synchronous or metachronous metastases or local recurrence of pancreatic adenocarcinoma

You may qualify if:

• \- Patients who had resection or destruction of one or more synchronous or metachronous metastases or local recurrence of pancreatic adenocarcinoma
• Details:
• synchronous lesions, metachrones can be included
• all distant lesions (hepatic, pulmonary) can be included
• documented lymph node involvement after analysis of the specimen (hepatic hilum, mesenteric root, retroperitoneal or inter-aortic-cellar) can be included
• patients with local recurrence who underwent surgical treatment

You may not qualify if:

• \- Patient who reject the study protocol

Sponsors & Collaborators

• University Hospital, Montpellier: lead
• Université Montpellier: collaborator
• Association de Chirurgie hepato-bilio-pancreatique et transplantation (ACHBT): collaborator
• Federation de recherche en chirurgie digestive (FRENCH): collaborator
• Club Français du Pancreas (CFP): collaborator

Study Sites (1)

Uhmontpellier

Montpellier, 34295, France

Location

MeSH Terms

Conditions

Pancreatic Neoplasms

Condition Hierarchy (Ancestors)

Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Endocrine Gland Neoplasms; Digestive System Diseases; Pancreatic Diseases; Endocrine System Diseases

Study Officials

• REGIS SOUCHE

  University Hospital, Montpellier

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 10, 2019
• First Posted: December 12, 2019
• Study Start: January 1, 2020
• Primary Completion: March 1, 2020
• Study Completion: December 1, 2020
• Last Updated: December 29, 2020

Record last verified: 2020-12

Locations

FR (1)